biotech
ADC Therapeutics S.A.
Sponsor view across the ADC target screen, including linked targets and source-linked trial evidence.
ADC target activity
Tracked targets
| Target | Trial count | Evidence |
|---|---|---|
| HER2 / ERBB2 | 1 | Source |
Linked trials
Clinical evidence links
- NCT02669017: Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) (COMPLETED)
- NCT04970901: A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (RECRUITING)
- NCT03125200: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (TERMINATED)
- NCT04052997: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (COMPLETED)